NCT03861936 - BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

April 3, 2020

Study Completion Date

July 2, 2020

Conditions

Masseter Muscle Prominence

Interventions

BIOLOGICAL

OnabotulinumtoxinA

OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.

DRUG

Normal saline

Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.

Trial Locations (14)

Baumann Cosmetic and Research Institute, Miami

Total Skin & Beauty Dermatology Center, PC, Birmingham

Nashville Centre for Laser and Facial Surgery, Nashville

DeNova Research, Chicago

Saint Louis University Dermatology, St Louis

Skin Specialists, PC, Omaha

Etre, Cosmetic Dermatology and Laser Center, New Orleans

Bellaire Dermatology Associates, Bellaire

Austin Institute for Clinical Research, Inc., Pflugerville

DermResearch, Inc., Austin

Advanced Clinical Research Gateway Aesthetic Institute & Laser Center, Salt Lake City

Westside Aesthetics, Los Angeles

Skin Care and Laser Physicians of Beverly Hills, Los Angeles

Cosmetic Laser Dermatology, San Diego